YMYasuhiro Magata

Yasuhiro Magata

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yasuhiro Magata has a total of 118 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Development of radioiodinated lipophilic cationic compounds for myocardial imaging

    by Toshihiro Sakai, Yuriko Saito, Misato Takashima, Mikako Ogawa, Yasuhiro Magata


  • Development of Radioligands for In Vivo Imaging of NMDA Receptors

    by Takeshi Fuchigami, Morio Nakayama, Yasuhiro Magata

  • Differentiation of tumor sensitivity to photodynamic therapy and early evaluation of treatment effect by nuclear medicine techniques

    by Jie Liu, Mikako Ogawa, Toshihiro Sakai, Misato Takashima, Shigetoshi Okazaki, Yasuhiro Magata

    Objective Our final goal is to develop an appropriate method using nuclear medicine technique for monitoring the effect and prediction of Photodynamic Therapy (PDT) on tumors. The aim of this study is to evaluate the effect of PDT on tumor cells in vitro using 18F-FDG and 99mTc-MIBI as tracers. Methods Five tumor cell lines (A431, DU145, H1650, LS180, SHIN3) with varied characteristics were irradiated after incubating for 24 h with several doses of Photofrin (PF). Singlet oxygen was monitored by the near-IR emission detection system during irradiation and generated 1O2 was calculated. PDT effects were rapidly evaluated by nuclear medicine techniques (uptake of 18F-FDG and 99mTc-MIBI) and traditional methods for cell viability (MTT and trypan blue assays) at 3 h after PDT. Intracellular PF concentration was measured by absorption spectrometer and cell protein content was measured by the Lowry method. 18F-FDG uptake, 99mTc-MIBI uptake, singlet oxygen, and intracellular PF concentration were standardized by protein content. Decrease % of 18F-FDG and 99mTc-MIBI, MTT, and trypan blue was normalized to the control group. Results Decrease % of 18F-FDG was exponentially related to decrease % of MTT (R 2 = 0.650, P < 0.01) while decrease % of 99mTc-MIBI was linearly related to that of MTT (R 2 = 0.719, P < 0.01). The decrease % of MTT was more sensitive than that of trypan blue. However, neither 1O2 nor PF uptake was correlated with sensitivity to PDT. In addition, 18F-FDG uptake before PDT was linearly related to decrease % of MTT (R 2 = 0.800, P < 0.05). Conclusions Our findings in in vitro studies suggest that 99mTc-MIBI is better than 18F-FDG for early evaluation of PDT effect, but 18F-FDG uptake may be used to predict PDT sensitivity before therapy.


  • Open Access

    Synthesis and evaluation of 2-chloro N-[(S)-{(S)-1-[11 C]methylpiperidin-2-yl} (phenyl)methyl]3-trifluoromethyl-benzamide ([11 C]N-methyl-SSR504734) as a PET radioligand for glycine transporter 1

    by Takeshi Fuchigami, Akihiro Takano, Balázs Gulyás, Zhisheng Jia, Sjoerd J Finnema, Jan D Andersson, Ryuji Nakao, Yasuhiro Magata, Mamoru Haratake, Morio Nakayama, et al.

    Background: Dysfunction of the glycine transporter 1 (GlyT1) has been suggested to be involved in psychiatric disorders such as schizophrenia. GlyT1 inhibitors have therefore been considered to have antipsychotic therapeutic potential. Positron emission tomography (PET) imaging probes for GlyT1 are, consequently, expected to be useful for investigating the mechanism of such disease conditions and for measuring occupancy of GlyT1 inhibitorsin vivo. The aim of this study was to assess the potential of 2-chloroN-[(S)-{(S)-1-[11 C]methylpiperidin-2-yl} (phenyl)methyl] 3-trifluoromethyl-benzamide ([11 C]N-methyl-SSR504734) as a PET imaging agent for GlyT1.Methods: [11 C]N-methyl-SSR504734 was synthesized byN-[11 C]methylation of SSR504734 via [11 C]CH3OTf.In vitrobrain distribution of [11 C]N-methyl-SSR504734 was tested in whole-hemisphere autoradiography (ARG) on human brain slices. Initial PET studies were performed using a cynomolgus monkey at baseline and after pretreatment with 0.1 to 1.5 mg/kg of SSR504734. Then, PET studies using rhesus monkeys were performed with arterial blood sampling at baseline and after pretreatment with 1.5 to 4.5 mg/kg SSR504734. Distribution volumes (VT) were calculated with a two-tissue compartment model, and GlyT1 occupancy by SSR504734 was estimated using a Lassen plot approach.Results: [11 C]N-methyl-SSR504734 was successfully synthesized in moderate radiochemical yield and high specific radioactivity. In the ARG experiments, [11 C]N-methyl-SSR504734 showed specific binding in the white matter and pons. In the initial PET experiments in a cynomolgus monkey, [11 C]N-methyl-SSR504734 showed high brain uptake and consistent distribution with previously reported GlyT1 expressionin vivo(thalamus, brainstem > cerebellum > cortical regions). However, the brain uptake increased after pretreatment with SSR504734. Further PET studies in rhesus monkeys showed a similar increase of brain uptake after pretreatment with SSR504734. However, theVTof [11 C]N-methyl-SSR504734 was found to decrease after pretreatment of SSR504734 in a dose-dependent manner. GlyT1 occupancy was calculated to be 45% and 73% at 1.5 and 4.5 mg/kg of SSR504734, respectively.Conclusions: [11 C]N-methyl-SSR504734 is demonstrated to be a promising PET radioligand for GlyT1 in nonhuman primates. The present results warrant further PET studies in human subjects.


  • Quantification of regional myocardial oxygen metabolism in normal pigs using positron emission tomography with injectable 15O-O2

    by Takashi Temma, Hidehiro Iida, Takuya Hayashi, Noboru Teramoto, Youichiro Ohta, Nobuyuki Kudomi, Hiroshi Watabe, Hideo Saji, Yasuhiro Magata


  • Open Access

    Estimation of Oxygen Metabolism in a Rat Model of Permanent Ischemia Using Positron Emission Tomography with Injectable 15O-O2

    by Takashi Temma, Yasuhiro Magata, Yuji Kuge, Sayaka Shimonaka, Kohei Sano, Yumiko Katada, Hidekazu Kawashima, Takahiro Mukai, Hiroshi Watabe, Hidehiro Iida, et al.

    The threshold of cerebral blood flow (CBF) into infarction in rats has been indicated to be similar to that in patients. However, CBF does not reflect metabolic function, and so estimations of oxygen metabolism have been required. Here, we estimated changes in oxygen metabolism after occluding the right middle cerebral artery (MCA) in rats using an injectable 15O-O2 we developed. A decrease in CBF (left: 0.67±0.22 mL/min/g, right: 0.44±0.17 mL/min/g, P < 0.05) and compensatory increase in the oxygen extraction fraction (OEF) (left: 0.42±0.13, right: 0.50±0.19, P < 0.05) were observed at 1-h after occlusion. In contrast, a marked decrease in CBF and the cerebral metabolic rate for oxygen and a collapse of the compensatory OEF mechanism were found at 24 h after occlusion. Injectable 15O-O2 could be used to reliably estimate oxygen metabolism in an infarction rat model with positron emission tomography.


    • 1 November 2006
      • Vol. 47  (11) , 1845-50

    Application of 18F-FDG PET for monitoring the therapeutic effect of antiinflammatory drugs on stabilization of vulnerable atherosclerotic plaques.

    by Mikako Ogawa, Yasuhiro Magata, Takashi Kato, Kentaro Hatano, Seigo Ishino, Takahiro Mukai, Masashi Shiomi, Kengo Ito, Hideo Saji

    The rupture of atherosclerotic vulnerable plaques and subsequent formation of thrombi are the main factors responsible for myocardial and cerebral infarctions. Because macrophage infiltration plays an essential role in plaque rupturing, pharmacologic therapy that reduces macrophage infiltration is required to stabilize the vulnerable plaques. The monitoring of therapeutic effect is important in assessing the therapeutic effects of drugs for individual patients. We previously reported that (18)F-FDG accumulates in macrophage-rich plaques. The present study was undertaken to investigate the usefulness of (18)F-FDG PET for monitoring therapies that target vascular inflammation. Myocardial infarction-prone Watanabe heritable hyperlipidemic rabbits were used in this study. The antioxidant probucol was included in the diet fed to 4 rabbits starting at 10 mo of age (probucol group). In a control study, 4 rabbits received standard rabbit chow (control group). (18)F-FDG PET experiments were performed on both groups before the study and at 1, 3, and 6 mo after treatment. After the last imaging session, the rabbits were sacrificed at 3 h after injection of (18)F-FDG, and the aortas were removed. The accumulated radioactivity was then measured, and the number of macrophages was determined by examination of stained sections. At the age of 10 mo, before the treatment, the aorta could be imaged by (18)F-FDG PET in all rabbits. The aorta could not be imaged after 6 mo of probucol treatment, whereas intense radioactivity was observed in the control rabbits throughout the investigation. The standardized uptake values (SUVs) of the aorta were decreased significantly in the probucol group after 3 mo of intervention as compared with the pretreatment period. The SUVs of the control group were increased gradually at 6 mo. Radioactivity in the aorta was significantly lower in the probucol group than that in the control group. Macrophages were already present at the beginning of the study, and probucol treatment for 6 mo resulted in a significant reduction of macrophage infiltration. (18)F-FDG PET was able to image the reduction of inflammation by probucol. (18)F-FDG PET should be useful for evaluating the therapeutic effect of drugs clinically and for the development of new drugs that can stabilize vulnerable plaques. (18)F-FDG PET should be useful for evaluating the therapeutic effect of drugs clinically and for the development of new drugs that can reduce inflammation of vulnerable plaques.


  • Understanding of cerebral energy metabolism by dynamic living brain slice imaging system with [18F]FDG

    by Mikako Ogawa, Hiroshi Watabe, Noboru Teramoto, Yoshinori Miyake, Takuya Hayashi, Hidehiro Iida, Tetsuhito Murata, Yasuhiro Magata


    • 1 July 2004
      • Vol. 45  (7) , 1245-50

    (18)F-FDG accumulation in atherosclerotic plaques: immunohistochemical and PET imaging study.

    by Mikako Ogawa, Seigo Ishino, Takahiro Mukai, Daigo Asano, Noboru Teramoto, Hiroshi Watabe, Nobuyuki Kudomi, Masashi Shiomi, Yasuhiro Magata, Hidehiro Iida, et al.

    The rupture of atherosclerotic plaques and the subsequent formation of thrombi are the main factors responsible for myocardial and cerebral infarctions. Thus, the detection of vulnerable plaques in atherosclerotic lesions is a desirable goal, and attempts to image these plaques with (18)F-FDG have been made. In the present study, the relationship between the accumulation of (18)F-FDG and the biologic characteristics of atherosclerotic lesions was investigated. Furthermore, PET imaging of vulnerable plaques was performed with an animal model of atherosclerosis, Watanabe heritable hyperlipidemic (WHHL) rabbits. WHHL (n = 11) and control (n = 3) rabbits were injected intravenously with (18)F-FDG, and the thoracic and abdominal aortas were removed 4 h after injection. The accumulated radioactivity was measured, and the number of macrophages and the intimal area were investigated by examination of stained sections. PET and CT images were also acquired at 210 min after injection of the radiotracer. (18)F-FDG accumulated to a significantly higher level in the aortas of the WHHL rabbits (mean +/- SD differential uptake ratio [DUR], 1.47 +/- 0.90) than in those of the control rabbits (DUR, 0.44 +/- 0.15); DUR was calculated as (tissue activity/tissue weight)/(injected radiotracer activity/animal body weight), with activities given in becquerels and weights given in kilograms. (18)F-FDG uptake and the number of macrophages were strongly correlated in the atherosclerotic lesions of the WHHL rabbits (R = 0.81). In the PET analysis, intense (18)F-FDG radioactivity was detected in the aortas of the WHHL rabbits, whereas little radioactivity was seen in the control rabbits. The results suggest that macrophages are responsible for the accumulation of (18)F-FDG in atherosclerotic lesions. Because vulnerable plaques are rich in macrophages, (18)F-FDG imaging should be useful for the selective detection of such plaques.


    • 1 May 2004
      • Vol. 45  (5) , 730-8

    Effect of caffeine intake on myocardial hyperemic flow induced by adenosine triphosphate and dipyridamole.

    by Shigeto Kubo, Eiji Tadamura, Hiroshi Toyoda, Marcelo Mamede, Masaki Yamamuro, Yasuhiro Magata, Takahiro Mukai, Haruhiro Kitano, Nagara Tamaki, Junji Konishi

    The aims of this study were (a). to compare absolute myocardial blood flow (MBF) during adenosine triphosphate (ATP) infusion with that after dipyridamole administration without caffeine intake and (b). to evaluate the effect of caffeine intake on the hyperemic flow induced by these coronary vasodilator agents. MBF was quantified with (15)O-labeled water and PET at rest, during ATP infusion (0.16 mg/kg/min for 9 min), and after dipyridamole administration (0.56 mg/kg over 4 min) after a 24-h abstinence from caffeine (baseline evaluation) in 10 healthy volunteers. Within 2 wk, the same PET studies were repeated after caffeine intake to evaluate the effect of caffeine on the hyperemic flow induced by these pharmacologic agents (caffeine study). Myocardial flow reserve (MFR), defined as the ratio of hyperemic to resting blood flow, was also evaluated. Resting MBF in baseline and caffeine studies did not differ significantly (0.79 +/- 0.29 vs. 0.75 +/- 0.31 mL/min/g, P = 0.88). Without caffeine intake, MBF during ATP infusion was significantly higher than that after dipyridamole administration (3.70 +/- 0.67 vs. 3.00 +/- 0.79 mL/min/g, P = 0.003), whereas there was no significant difference in MFR between ATP and dipyridamole stress (5.15 +/- 1.64 vs. 4.11 +/- 1.44, P = 0.07). After caffeine intake, the hyperemic flows induced by ATP and dipyridamole were not significantly different (1.68 +/- 0.37 vs. 1.52 +/- 0.40 mL/min/g, P = 0.50). MFR estimated by ATP and dipyridamole also did not differ significantly in the caffeine studies (2.44 +/- 0.88 vs. 2.25 +/- 0.94, P = 0.73). MBF during ATP infusion and after dipyridamole administration were significantly lower in the caffeine studies than that in the baseline evaluation (1.68 +/- 0.37 vs. 3.70 +/- 0.67 mL/min/g, P < 0.0001, and 1.52 +/- 0.40 vs. 3.00 +/- 0.79 mL/min/g, P < 0.0001, respectively). This study demonstrates that ATP has the potential to induce greater hyperemia than dipyridamole, whereas hyperemic responses to ATP and dipyridamole are similarly attenuated after caffeine intake. These findings suggest that abstinence from caffeine before ATP stress testing may be needed.